CPC C07K 16/2803 (2013.01) [A61K 38/2013 (2013.01); A61K 38/2026 (2013.01); A61K 38/2066 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5088 (2013.01); G01N 33/5091 (2013.01); G01N 33/56972 (2013.01); G01N 33/57407 (2013.01); G01N 33/57438 (2013.01); G01N 33/57484 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] | 3 Claims |
1. A method for treating renal cell carcinoma in a human comprising administering, to said human, an anti-PD-1 antibody that interferes with an interaction between B7-H1 and PD-1, wherein some or all cells of said renal cell carcinoma express B7-H1.
|